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Abstract
Background: Acute critical bleeding is one of the most feared complications during treatment with oral
anticoagulating agents. As more patients undergo treatment with anticoagulating agents, critically bleeding
episodes in patients with vitamin K antagonists, thrombin inhibitor, or factor Xa inhibitor-inducted coagulopathy
will be encountered frequently by physicians. Hence, an effective treatment capable of reversing the iatrogenic
coagulopathy in the acute setting is needed. In randomised clinical trials and observational studies, prothrombin
complex concentrate has been reported to be superior to other acute interventions, and many guidelines
recommend prothrombin complex concentrate in treatment of critically bleeding patients. The aim of this
systematic review is to synthesise the evidence of the effects of prothrombin complex concentrate compared with
placebo, no intervention, or other treatment options in critically bleeding patients treated with oral anticoagulants.
Methods/design: A comprehensive search for relevant published literature will be undertaken in Cochrane Central
Register of Controlled Trials, MEDLINE, Embase, WHO International Clinical Trials Registry Platform, Science Citation
Index, regulatory databases, and trial registers. We will include randomised clinical trials comparing prothrombin
complex concentrate versus placebo, no intervention, or other interventions in critically bleeding patients with oral
anticoagulant-induced coagulopathy. Data extraction and risk of bias assessment will be handled by two
independent review authors. Meta-analysis will be performed as recommended by Cochrane Handbook for
Systematic Reviews of Interventions, bias will be assessed with domains, and trial sequential analysis will be
conducted to control random errors. Certainty will be assessed by GRADE.
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Discussion: As critical bleeding in patients treated with oral anticoagulants is an increasing problem, an up-to-date
systematic review evaluating the benefits and harms of prothrombin complex concentrate is urgently needed. It is
the hope that this review will be able to guide best practice in treatment and clinical research of these critically
bleeding patients.
Systematic review registration: PROSPERO CRD42018084371
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Background
The drug class of oral anticoagulants consists of vitamin
K antagonists or non-vitamin K antagonists.
Vitamin K antagonists (e.g. warfarin) are a well-known
class of anticoagulants prescribed for a wide range of condi-
tions related to risk of thrombosis or emboli. It affects the
coagulation cascade by inhibiting the enzyme vitamin K ep-
oxide reductase preventing the synthesis of the biologically
active forms of the clotting-factors II, VII, IX, and X [1].
Patients treated with vitamin K antagonists are at a
relative high risk of haemorrhagic complications related
to the iatrogenic coagulopathy. Recent results from a
large Swedish registry reported an annual incidence of
any haemorrhagic complication of 2.23% (95% CI 2.11 to
2.34%) [2]. One of the most dreaded complications to
vitamin K antagonists is intracranial haemorrhage. The
annual incidence of intracranial haemorrhagic in the
previous mentioned study was reported to 0.44% (95%
CI 0.39 to 0.49%). However, it is relatively well-accepted
that the risk of haemorrhagic complications can be sig-
nificantly mitigated by maintaining international normal-
ised ratio (INR) within the desired range [2–4].
Non-vitamin K antagonist oral anticoagulants (NOAC)
have gained increasing popularity in recent years [5–7].
In at least three Cochrane reviews, NOACs showed
non-inferiority compared with warfarin [7–10]. A net-
work meta-analysis claimed superiority of NOAC over
warfarin, when adding together the net benefits of pro-
tection of embolic events and less bleeding in patients
with atrial fibrillation [6].
Two general classes of NOAC exist: direct thrombin
(factor IIa) inhibitors (e.g. dabigatran) and factor Xa inhib-
itors (rivaroxaban, apixaban, betrixaban, and edoxaban).
Now, factor XI inhibitors are on the way – and we expect
larger trials on these soon [11, 12]. The direct thrombin
inhibitor dabigatran functions by competitive inhibition of
the active site on the thrombin molecule [13]. The factor
Xa inhibitors inhibit the coagulation cascade by competi-
tively binding to the active site of factor Xa [13].
Haemorrhagic complications
When patients on oral anticoagulants present with
critical bleeding, the ability to reverse the iatrogenic
coagulopathy in the acute hospital setting is important.
Studies have shown that patients with vitamin K
antagonists-associated intracerebral haemorrhage suffer
larger admission haematoma volumes and have a greater
tendency to undergo post-admission haematoma expan-
sion compared to patients not treated with oral antico-
agulants [14–17]. Post-admission haematoma expansion
is consistently linked to neurological deterioration and
poor functional outcome [18–21] and hence an import-
ant mediator in the association between anticoagulation
treatment and poor outcome in intracerebral haemor-
rhage patients. A fast and efficient method to reverse the
coagulopathy is warranted, if such a methods exists,as
the probability of haematoma expansion is linked dir-
ectly to the time spend before reversal of the coagulopa-
thy is achieved [22].
Meta-analysis of randomised clinical trials investigat-
ing NOAC versus vitamin K antagonists for various
thrombotic indications finds the risk of bleeding epi-
sodes significantly lower among patients treated with
NOAC (pooled odds ratio 0.36 (95% CI 0.15 to 0.84))
[23]. This notion is supported by a recent network
meta-analysis for several of the individual NOACs [6].
Patients treated with NOAC have in small observational
studies been found to present with smaller intracerebral
haematomas on admission compared to patients
pre-treated with warfarin [24–27], however, haematoma
expansion seems to happen almost as frequently [28,
29]. It is possible that these observational studies could
suffer from confounding by indication and that temporal
changes in treatment-guidelines could skew the results
in favour of NOAC. A meta-analysis of randomised clin-
ical trial data has not been able to show a difference in
clinical outcome of patients suffering intracerebral
haemorrhage, while being treated with NOAC compared
with vitamin K antagonists [30].
Reversal strategies (experimental interventions)
Different reversal strategies have been suggested and
employed in the clinical setting, when treating vitamin K
antagonists associated bleeding: stopping the vitamin K an-
tagonist therapy, administration of phytomenadion (vitamin
K), administration of fresh frozen plasma, or administration
of prothrombin complex concentrate [31, 32]. Simply stop-
ping the therapy with vitamin K antagonists will cause
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normalisation of the coagulation cascade over the course of
days dependent on especially the weekly warfarin dose and
the baseline international normalised ratio [33, 34]. The
normalisation of the coagulation cascade is a function of
the half-life of warfarin (approximately 35 to 45 h) and the
synthesis of coagulation factors in the liver [34]. Phytome-
nadion as monotherapy has in both observational studies
and randomised trials been shown effective in controlling
excessive anticoagulantion (excessively raced INR) in
non-critically bleeding patients [35–37], but to our know-
ledge, it has never been tested as monotherapy in critically
bleeding patients. In randomised clinical trials, it has never
been shown that factor replacement with either fresh frozen
plasma or prothrombin complex concentrate is superior in
terms of limiting morbidity and mortality to simply stop-
ping the vitamin K antagonist therapy or administering
phytomenadion alone. Guidelines have, however, consist-
ently recommended using either fresh frozen plasma or
prothrombin complex concentrate in addition to stopping
the therapy, when treating critically bleeding patients
treated with vitamin K antagonists, as replacement of the
coagulation factors is deemed necessary in order to achieve
an effective haemostasis [38, 39]. Many sources do recom-
mend combining the administration of coagulation factors
with phytomenadion, when treating critically bleeding pa-
tients on vitamin K antagonists. This is due to an observed
re-increase in INR after 12 to 24 h in patients treated with
coagulation factor replacement alone [40]. For a long time,
one of the most commonly accepted reversal strategies
used, when patients suffered serious haemorrhagic compli-
cations to vitamin K antagonists therapy, has been the ad-
ministration of fresh frozen plasma collected from healthy
donors [38]. Fresh frozen plasma replaces the coagulation
factors that have been pharmacologically depleted from the
vitamin K antagonists treated patients’ coagulation cascade.
However, rapid administration of fresh frozen plasma might
be hampered by blood type matching, maximal acceptable
administration pace, and possible complications related to
fluid overload [41].
During recent years, the use of prothrombin complex
concentrate has come into use in critically bleeding pa-
tients. Prothrombin complex concentrate contains a
collection of either three coagulation factors (II, IX,
and X) or four coagulation factors (II, VII, IX, and X)
in a concentration approximately 25 times higher than
normal plasma [31]. Prothrombin complex concentrate
might be a more attractive alternative compared with
fresh frozen plasma. Prothombin complex concentrate
does not require blood type matching, a lower volume
is required making the risk of fluid overload smaller,
and the risk of infections might be lower as prothrom-
bin complex concentrate undergoes viral inactivation
procedures [31, 42]. Observational [43–48] and rando-
mised [49–51] evidence indicates that prothrombin
complex concentrate might reverse the raised INR
quicker compared to fresh frozen plasma. This can
possibly be translated into a lower morbidity and mor-
tality in patients treated with prothrombin complex
concentrate.
In NOAC-treated patients, one of the most persistent
concerns to clinicians has been the lack of an effective
technique allowing a swift reversal of the iatrogenic
coagulopathy in case of critical bleeding episodes.
Eerenberg et al. [52] showed that a relatively effective
biochemical reversal of the coagulopathy inflicted on
healthy volunteers by pre-treatment with the factor Xa
inhibitor rivaroxaban was possible by administrating
prothrombin complex concentrate. Healthy volunteers
pre-treated with dabigatran did, however, not obtain the
same reversal effect. Boehringer Ingelheim (Germany)
has released a monoclonal antibody fragment—idaruci-
zumab—which has been shown effective at normalising
the utilised coagulation assay (diluted thrombin time
and ecarin clotting time) in critically bleeding patients
pre-treated with dabigatran [53, 54]. Idarucizumab is
now marketed and can be used in clinical practice.
Other biological antidotes proposed are andexanet alfa
(Portola Pharmaceuticals, CA, USA) and ciraparantag
(Perosphere, CT, USA) [55]. Andexanet alfa has been
shown effective in normalising the utilised coagulation
assay (chromogenic anti-factor Xa assay) in critically
bleeding patients pre-treated with factor Xa inhibitors
[56] even though some rebound of the anticoagulating
effect seems to happen after end-of-infusion [56, 57].
Andexanet alfa has recently been approved by the
United States Food and Drug Administration (media re-
lease, May 2018, http://www.portola.com). Ciraparantag
(PER977) is a synthetic molecule that binds factor Xa in-
hibitors, direct thrombin inhibitors, and unfractionated
as well as low molecular weight heparins [55]. Even
though not proven effective in a critically bleeding pa-
tient population, ciraparantag has been shown effective
in normalising the utilised coagulation assay (whole
blood clotting time) in healthy volunteers pre-treated
with endoxaban [58]. In addition to reversal of NOAC
using biological antidotes, a trial is currently being con-
ducted aiming at investigating, if tranexamic acid can
limit haematoma growth in patients, who develop intra-
cerebral haemorrhage while being treated with NOAC—
the TICH-NOAC trial (NCT02866838, November 2017).
To our knowledge, neither prothrombin complex con-
centrate, idarucizumab nor andexanet alfa have been
shown effective on patient-relevant outcomes in treating
NOAC-related critical bleeding. However, guidelines rec-
ommend the use of prothrombin complex concentrate
in patients suffering intracerebral haemorrhage pre-
treated with factor Xa inhibitors and idarucizumab in
patients pre-treated with dabigatran [39].
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Another important aspect to consider when administer-
ing factor replacement (fresh frozen plasma or prothrombin
complex concentrate) or when using other measures to re-
verse anticoagulation treatment is the risk of inducing
thromboembolic events. Patient populations being treated
with anticoagulants are likely at an increased risk of
thromboembolic complication due to the indication of
anticoagulation treatment (atrial fibrillation, mechanical
heart valves, etc.). By discontinuing the anticoagulation
treatment, it is likely that we expose the patients to an in-
creased risk of thromboembolic events. Moreover, the risk
of thromboembolic events can presumably be aggravated
even further by administration of factor replacement [59],
especially if high-dose regimens are used [60].
Why is it important to do this review?
It is essential to establish, if the apparent effect of
prothrombin complex concentrate in reversing vita-
min K antagonists and NOAC induced coagulopathy
translates into changes in functional outcome or mor-
tality. In addition, a synthesis of the randomised clin-
ical trials might allow us to assess the safety profile
of the different treatment options directly. A
Cochrane review from 2015 [61] assessed the com-
parison of prothrombin complex concentrate with
fresh frozen plasma. However, this review did not
specifically assess the effects of prothrombin complex
concentrate versus fresh frozen plasma in the sub-
group of patients with intracranial haemorrhage. This
complication is especially dreaded. Moreover, a pre-
liminary search has also identified new trials since the
last update of this review [51]. Another systematic re-
view published in 2017 conducted by Brekelman et al.
[62] focused on four-factor prothrombin complex
concentrate and did mostly include observational
studies. The systematic literature search conducted by
the authors ended in August 2015 before publication
of the INR normalisation in patients with coumarin-
related intracranial haemorrhages trial (INCH trial)
[51]. The present systematic review aims at forming
the basis for evidence-based guideline recommenda-
tions for treatment of oral anticoagulant-associated
critical bleeding using prothrombin complex concen-
trate taking bias risks (systematic errors), play of
chance (random errors), and certainty of the findings
into consideration.
Objectives
The objective of this review will be to assess the
beneficial and harmful effects of prothrombin com-
plex concentrate compared with placebo, no interven-
tion, or other interventions in critically bleeding
patients treated with oral anticoagulants.
Methods
Types of studies
Randomised clinical trials will be considered for assess-
ment of benefits and harms. By focusing on randomised
clinical trials, we are aware that our focus will be more
on benefits than on harms and that rare or late adverse
events might be missed.
Types of participants
We intend to include patients with the following
characteristics:
 Critical haemorrhage from any location. We define
critical bleeding as external or internal haemorrhage
indicating acute reversal of the iatrogenic
coagulopathy (as defined by trialists).
 Any oral anticoagulant, e.g. vitamin K antagonist or
NOAC treatment at the start of the bleeding (as
defined by trialists).
Types of interventions
Experimental group
Prothrombin complex concentrate. We will include trials
regardless of dose, type of prothrombin complex con-
centrate (three or four factors, inactivated or activated),
and administration regime utilised.
Control groups
We will include trials utilising the options listed below
as control intervention:
1. Placebo or no intervention.
2. Fresh frozen plasma.
3. Vitamin K or phytomenadione.
4. Other interventions (e.g. recombinant factor VII,
tranexamic acid, or biological antibodies).
Co-interventions
Pre-specified co-interventions will be allowed, if they are
planned to be administered equally in both intervention
groups, e.g. phytomenadione/vitamin K. Rescue inter-
ventions will be allowed and reported.
Outcomes
Primary outcomes
 All-cause mortality.
 Health-related quality of life (any valid patient-
reported continuous scale used by the trialists).
 Proportion of participants with one or more serious
adverse events. We will define a serious adverse event
as any untoward medical occurrence that resulted in
death, was life-threatening, required hospitalisation or
prolongation of existing hospitalisation, or resulted in
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persistent or significant disability or incapacity
(ICH-GCP 1997).
Secondary outcomes
 Poor functional outcome on the modified Rankin
Scale (mRS) or the Glasgow Outcome Scale (GOS)
(as defined by the trialist). If no cut-point is defined
by the trialist, mRS 4–6 and GOS 1–3 will be used.
If other functional outcome scale is used, they will
be included, if dichotomisation is reported by the
trialist.
 Proportion of participants with at least one
thromboembolic event during the follow-up period
(as defined by the trialist).
 Proportion of participants with allergic reaction (as
defined by the trialist).
 Proportion of participants with pulmonary oedema
(as defined by the trialist).
All primary and secondary outcomes will be assessed at
maximum follow-up. Primary and secondary outcomes
are all deemed ‘patient-important’ and ‘critical’ [63].
Exploratory outcomes
 INR correction not achieved within 3 h after
infusion start. If this information is not available,
reported INR correction between 0.5–6 h after
infusion start can be included. INR correction will
be defined as described in the included study. If no
INR correction level is pre-defined, INR ≤ 1.2 will be
used.
 Haemostatic efficacy/haematoma expansion as
defined by the trialist. The assessment performed
closest to 24 h after admission will be used, if
multiple assessments are reported. If the trialists do
not utilise a definition of haemostatic efficacy or
haematoma expansion, we will utilise the definition
of haemostatic efficacy proposed by Sarode et al.
[50]. If trials utilise multiple definitions of
haemostatic efficacy/haematoma expansion, we will
use the one most identical to the haemostatic
efficacy definition by Sarode et al. [50].
 Number of patients receiving ≥ 1 transfusion of
packed red blood cells within the maximum follow-
up period.
Literature database searches
We will search the following literature databases using a
pre-specified search strategy:
Cochrane Central Registry of Controlled Trials (CEN-
TRAL), Ovid MEDLINE(R) Epub Ahead of Print, In-Process
& Other Non-Indexed Citations, Ovid MEDLINE(R) Daily,
Ovid MEDLINE and Versions(R), EMBASE (OVIDSP),
WHO International Clinical Trials Registry Platform
(ICTRP), and Science Citation Index (Web of Science).
All databases will be searched from the earliest avail-
able issue. Draft of search strategy is presented in
Additional file 1.
We will also search company websites as well as regu-
latory authorities in USA, EU, India, China, Japan, and
Australia-New Zealand.
The reference lists of the identified reports will be
searched for possibly missed trials. Experts within the
field will be asked to supply studies not identified by the
search. No language restrictions will be used. The pro-
posed search string is presented in the appendix.
Selection of trials
Two authors will independently screen all identified ref-
erence based on title and abstract in order to identify tri-
als potentially fulfilling the inclusion criteria (JP and
CO). Disagreement will be mediated by a third author
(JCJ) and solved by discussion.
The full paper of the potentially relevant references
will be provided. The two authors will make a final deci-
sion towards which trials fulfil the inclusion criteria.
Extraction of data
Data from included trials will be extracted by two inde-
pendent authors (JP and CO). Disagreement will be me-
diated by a third author (JCJ) and solved by discussion.
Data presented in graphs can be included, if they can be
read off in a precise manner. If any uncertainty exists,
the authors of the trial will be contacted. In the case that
needed data are not presented in the article, the authors
will be contacted.
The following data will be extracted from each in-
cluded trial:
Overall trial data: Name of first author, publication
year, duration of the trial, number of sites, number of
patients randomised in each arm, main indication for
treatment, age of participants, time to treatment.
Risk of bias: Besides the review authors’ overall assess-
ment of the risk of bias within each of the below listed
bias components (allocation sequence generation, alloca-
tion concealment, blinding of outcome assessors, incom-
plete outcome data, selective outcome reporting, vested
interest bias, and other sources of bias), the review au-
thor will substantiate his/her assessment by quotes taken
from the published study material or correspondence.
Treatment regime: Type of prothrombin complex concen-
trate (number of factors, activated/not activated), brand
name, standard prothrombin complex concentrate dose/re-
gime, standard control-treatment type/dose/regime, standard
pharmacological/haematological co-interventions (criteria,
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product, and dose), protocol for pharmacological/haemato-
logical rescue interventions (criteria, product, and dose).
Outcomes: For all the specified outcomes, we will log;
the definition of the outcome used by the trialists (in-
cluding length of the follow-up period). If the outcome
measure is dichotomous, the total number of patients
evaluated in each treatment group and the total number
of events in each treatment group are logged. If the out-
come measure is continuous, the mean or median as
well as standard deviation, standard error, range or con-
fidence interval will be logged.
In trials not following the Good Clinical Practice def-
inition of serious adverse events, the number of serious
adverse events will be defined by the sum of patients ex-
periencing untoward medical events that the two data
extractors will label as fulfilling the good clinical practice
definition of a serious adverse event. Differences will be
resolved by mediation by a third author (JCJ).
Conclusion: The key conclusion drawn by the authors
of the trial.
Risk of bias assessment
We will utilise the bias assessment tool presented in the
Cochrane Handbook for Systematic Reviews of Interven-
tions [64]. We choose to also assess vested interest bias,
as industry sponsorship has been shown to cause over-
estimation of the treatment effect independent of other
risk of bias domains [65, 66]. Vested interests conse-
quently impact internal validity in trials.
Numerous studies have concluded that trials at high
risk of bias overestimate the beneficial treatment effects
and underestimate the harmful effects [67–71]. Two re-
viewers will assess each included trial independent of
each other. The methodology of the individual trial will
be evaluated as to the risk of bias within the following
domains: Allocations sequence generation, allocation con-
cealment, blinding of participants and treatment pro-
viders, blinding of outcome assessors, incomplete outcome
data, selective outcome reporting, vested interest bias,
and other bias sources.
Allocation sequence generation
 Low risk of bias—the allocation sequence is generated
by a computer, random number table or similar.
Minimization will be considered equal to randomisation.
 Uncertain risk of bias—the trial is reported to utilise
a random allocation sequence or minimization, but
the method used for the allocation sequence
generation was not described.
 High risk of bias—a non-random system is used to
generate the allocation sequence (quasi-randomised
designs). Such trials will be excluded from assess-
ments of benefits.
Allocation concealment
 Low risk of bias—the allocation sequence was
concealed in a way that participants or investigators
could not have predicted the next treatment
allocation.
 Uncertain risk of bias—the method used to conceal
the allocation sequence is not described.
 High risk of bias—the allocation sequence could
have been foreseen by the investigators or
participants. Such trials will be excluded from
assessments of benefits.
Blinding of participants and treatment providers
 Low risk—if the participants and the personnel are
blinded to treatment allocation and this is described.
 Unclear risk—if there is insufficient information to
permit judgement of ‘low risk’ or ‘high risk’.
 High risk—if blinding of participants and personnel
is not performed or if allocation could be deducted,
e.g. by utilising no intervention as control treatment.
Blinding of outcome assessors
 Low risk of bias—the outcome assessors are blinded
and the method of blinding is described.
 Uncertain risk of bias—the outcome assessors are
blinded and the method of blinding is not described.
 High risk of bias—the outcome assessors are not
blinded.
Incomplete outcome data
 Low risk of bias—there are no post-randomisation
drop-outs/withdrawals or if missing outcome data
are balanced between intervention groups with simi-
lar reasons posted.
 Uncertain risk of bias—it is not clear, whether there
are any drop-outs or withdrawals or if the reasons
for these drop-outs are not clear.
 High risk of bias—the reasons for missing data are
likely to be related to true outcomes, ‘as-treated’
analysis is performed, potentially inappropriate
application of simple imputation, potential for
patients with missing outcomes to induce clinically
relevant bias.
Selective outcome reporting
 Low risk of bias—the trial’s protocol is available and
all of the trial’s pre-specified (primary and second-
ary) outcomes that are of interest in the review have
been reported in the pre-specified way. Alternatively,
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if the protocol is not available but the published re-
port contains all expected outcomes (including pre-
specified).
 Uncertain risk of bias—there is insufficient
information present to assess the risk of selective
outcome reporting.
 High risk of bias—not all the pre-specified outcomes
are reported, the primary outcomes are changed,
one or more primary outcomes were not pre-
specified or if some of the important outcomes are
incompletely reported.
Vested interest bias
 Low risk of bias—the trial is without funding or is
not funded by a pharmaceutical company or medical
manufacturer, who might have an interest in the
obtained results.
 Uncertain risk of bias—the source of funding is not
clear.
 High risk of bias—the trial is funded by a
pharmaceutical company or medical manufacturer,
who might have an interest in the obtained results.
Other sources of bias
If other sources of bias are evident, these sources will be
reported—and the consequences will be discussed.
Overall risk of bias
We will judge trials to be at ‘overall low risk of bias’, if they
are assessed as ‘low risk of bias’ in all the above domains.
We will judge trials to be at ‘overall high risk of bias’, if
they are assessed as having an unclear risk of bias or a
high risk of bias in one or more of the above domains.
As the risk of bias can vary between different out-
comes within the same trial, we will assess the domains
‘Blinding of outcome assessor’, ‘Incomplete outcome data’,
and ‘Selective outcome reporting’ for each outcome re-
sult. Thus, we will be able to assess the bias risk for each
outcome result in addition for each trial (overall risk of
bias of each trial). We will base our primary conclusions
on the outcome results of our primary outcomes with
low risk of bias.
Assessment of reporting bias
On all outcomes, we will construct funnel plots and
inspect for asymmetry. If more than ten trials are in-
cluded, a formal test for funnel plot asymmetry will
be conducted. Visually skewed funnel or a significant
test of asymmetry will be discussed. We recognised
that an asymmetric funnel plot does not necessarily
imply reporting bias, but can arise due to poor meth-
odology, inadequate analysis, small study effect, or
chance [72–74].
Data synthesis
Jakobsen and colleagues’ eight-step approach [75] repre-
sents a framework detailing, how reliable data synthesis can
be performed in systematic reviews with meta-analysis. Our
planned data synthesis is centred around these recommen-
dations. Details concerning the analysis process and data
synthesis are presented below.
Meta-analysis (fixed and random effect)
We will perform data syntheses in order to obtain a
pooled effect estimate of the treatment effect. We will
confer the recommendations in the Cochrane Handbook
for Systematic Reviews of Interventions [64]. We will both
perform fixed-effect and random-effects meta-analysis
[75]. Differences in pooled effect estimates obtained from
the two will be discussed [75]. We will primarily consider
the most conservative estimate as the primary result [75].
We will regard the most conservative estimate as the esti-
mate closest to zero effect. If the two pooled estimates are
equal, we will use the estimate with the widest CI.
In standard meta-analysis, trials presenting zero events
in one or both treatment arms can produce computa-
tional difficulties. The standard method in order to deal
with zero cells is to employ continuity correction by
adding 0.5 to zero cells [64, 76]. Continuity correction
can potentially bias results towards the null and inflate
variance. If we identify trials with zero events in one or
both intervention groups, a beta-binominal regression
analysis will be conducted as a supplementary analysis
[77–79]. If the result of the beta-binominal regression
differs from the traditional meta-analysis result, we will
discuss the implications thoroughly [77–79].
Adjusted threshold for significance
In order to avoid inflation of the type 1 error due to multi-
plicity, we plan to adjust the significance level used to de-
clare statistical significance [75]. As the Bonferroni
adjustment method is often considered too conservative
especially with correlated outcome measures, we plan to
use the pragmatic approach suggested by Jakobsen and
colleagues [75]. In order to adjust the risk of type 1 errors
for multiple comparisons, we divide the value by the value
halfway between 1 and the number of outcome compari-
sons. We assess three primary outcomes and four second-
ary, and we will consequently use 0.05/ 4 = 0.0125 as the
risk of type 1 error (alpha-level) [75]. A 10% risk of type 2
error (beta-level) will be used in all calculations [80].
Trial sequential analysis
Trial sequential analysis is a technique designed to re-
duce the risk of chance-finding (due to random error or
‘play of chance’) in meta-analysis [81–85]. Standard
meta-analysis is vulnerable to spurious finding, especially
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if a small number of patients are included or the partici-
pants are subject to multiple reanalyses [81–85].
In the trial sequential analysis, a meta-analytic sample
size calculation (required information size) is calculated
based on the expected or observed event rate within the
control population, the expected clinically relevant relative
risk reduction inflicted by the intervention, the chosen
type 1 error (alpha-level) and the power (1-beta) [83]. In
addition, this required information size is adjusted by the
observed diversity in the meta-analysis [86].
To deal with the problems of low power and re-
peated significance testing, the TSA controls the ac-
cepted significance threshold by utilising monitoring
boundaries, as long as the required information size
is not reached [82, 83, 85]. Consequently, the effect
of the intervention needs to provide a level of evi-
dence large enough to cross a reliably adjusted signifi-
cance threshold, before the intervention is considered
superior to the control treatment, if the required in-
formation size is not obtained.
In addition, an intervention cannot be considered to be
non-superior to the control, until a certain required infor-
mation size has been reached as the meta-analysis runs
the risk of type 2 error [83]. Analogue to the monitoring
boundaries, futility boundaries can be constructed. Below
this threshold, the probability of a significant treatment ef-
fect becomes so low that is can be ignored. It can hence
be concluded that the intervention does not possess an
intervention effect that is larger than or as large as the
one postulated in the sample size calculation [83].
We plan to calculate the required information sizes for
each outcome. The heterogeneity-adjusted information
size (APHIS) is based on an a priori defined clinically
relevant relative risk reduction of 20% for prothrombin
complex concentrate compared with control, and a con-
trol event proportion based on the pooled event propor-
tion in the control group. The proposed clinically
relevant relative risk reduction is in nature arbitrary, but
is proposed in the Grading of Recommendations,
Assessment, Development and Evaluation (GRADE)
Handbook [63]. When analysing continuous outcomes,
we define a clinically relevant mean difference as the ob-
served standard deviation divided by two [87] in accord-
ance with a distribution-based approach to clinically
relevant mean differences.
For all outcomes, trial sequential analysis-adjusted
confidence intervals will be reported.
Bayes factor
Bayes factor denotes the ratio between the probability of
the observed data given the null hypothesis and the
probability of the observed data given the alternative hy-
pothesis [88, 89]. It is hence a ratio of how compatible
two competing hypotheses are with the observed data
and consequently how much evidence is in support of
the null hypothesis versus the alternative hypothesis.
In the context of a meta-analysis, the null hypothesis
represents the hypothesis that the pooled effect of the
intervention is identical to the pooled effect of the con-
trol intervention (effect estimates for binary outcome
measures are in reality equal to the value 1.0, and con-
tinuous outcome measures are in reality equal to 0). The
alternative hypothesis is in this context defined as the ef-
fect size used, when calculating the required information
size [75].
An obtained low p value can be misleading [75, 90].
The observed p value could potentially be a type 1 error,
or affected by imbalance in important prognostic factors
due to a low number of randomised participants [91]. If
a very large treatment effect was anticipated in the cal-
culation of the required information size, even a statisti-
cally significant, but lower pooled effect estimate can be
more compatible with the null hypothesis [75, 90].
When the Bayes factor is 1.0, the amount of evidence
supporting the null hypothesis and the alternative hy-
pothesis is identical [90]. This can be interpreted as a
situation, in which the obtained effect size is halfway be-
tween null effect and the hypothesised effect size [90].
When Bayes factor is larger than 1.0, the evidence is in
support of the null hypothesis—and when lower than
1.0, the evidence is in support of the alternative
hypothesis.
We plan to calculate Bayes factor for all outcomes and
use a Bayes factor less than 0.1 as a threshold for signifi-
cance [75].
Missing data
If data needed are not available in the publications
spawned from the trial, the authors will be contacted
and the missing data will be requested.
Missing outcome data can potentially bias the effect
estimates in a trial and in a systematic review [92]. If
data are missing completely at random, the exclusions
will not bias the effect estimate [93]. However, situations
in which data can be said to be missing completely at
random are rare. In most situations, missing outcome
assessments are informatively missing—i.e. the probabil-
ity that an outcome is missing is related to the unseen
outcome per se [93]. An analysis not taking this into ac-
count runs the risk of bias.
If standard deviations of continuous outcomes are not
reported in the trial and cannot be retrieved, they will be
sought calculated from trial data. Is this calculation im-
possible, the standard deviation will be imputed from
similar trials.
To assess the potential impact of the missing outcome
data for dichotomous outcomes, we plan to perform the
two following sensitivity analyses [75, 93].
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 ‘Best-worst-case’ scenario: We will assume that the
outcome of all participants lost to follow-up will
favour the intervention in question, i.e. all lost to
follow-up in the experimental group have survived,
have had no serious adverse event, and suffered no
morbidity (for all dichotomous outcomes); and all
those participants with missing outcomes in the
control group have not survived, have had a serious
adverse event, and suffered morbidity (for all dichot-
omous outcomes).
 ‘Worst-best-case’ scenario: We will assume that all
participants lost to follow-up will favour the control,
i.e. all lost to follow-up in the experimental group did
not survive, had a serious adverse event, and suffered
morbidity (for all dichotomous outcomes); and that
all those participants lost to follow-up in the control
group had survived, had no serious adverse event, and
suffered morbidity (for all dichotomous outcomes).
When analysing continuous outcomes, a ‘beneficial
outcome’ will be the group mean plus two SDs (we will
secondly use one SD in another analysis) of the group
mean, and a ‘harmful outcome’ will be the group mean
minus two SDs (we will secondly use one SD in another
analysis) of the group mean [75].
We will present results from all scenarios in our
review.
Subgroup analyses
We plan to conduct the following subgroup analysis on
the chosen outcome measures:
 Trials at low risk of bias will be compared to trials at
high risk of bias. If no trials are at low risk of bias,
trials at relative lower risk of bias will be compared
to trials at high risk of bias.
 Trials using fresh frozen plasma as control
treatment compared to trials using other control
interventions.
 Participants falling within the strict critical bleeding
definition (listed below) compared to participants
that do not fall within the strict critical bleeding
definition (definition based on the GUSTO [94] and
CURE [95] bleeding classifications).
 A critically bleeding patient will be defined as
having either:
i. Life-threatening bleeding: Intracranial
bleeding, bleeding requiring surgical
intervention, bleeding that results in
substantial haemodynamic compromise
requiring acute treatment, or bleeding
deemed life-threatening by trialists.
ii. Major bleeding: Bleeding that causes
substantial decrease in haemoglobin (level of
decrease either ≥ 5 g/dL or as specified by
trialists) or requires blood product
transfusion.
iii. Sensitive organ bleeding: Intraocular bleeding,
intraspinal bleeding, pericardial bleeding or
similar.
 Participants treated with four-factor prothrombin
complex concentrate compared to participants
treated with three-factor prothrombin complex
concentrate.
 Participants with intracranial haemorrhage
compared to participants with other types of
bleeding.
 Participants treated with NOAC compared to
participants treated with vitamin K antagonists.
 Participants treated with factor Xa inhibitors
compared to participants treated with vitamin K
antagonists.
 Participants treated with factor IIa (direct thrombin)
inhibitors compared to participants treated with
vitamin K antagonists.
GRADE and summary of findings tables
The GRADE approach will be utilised to assess the qual-
ity of the body of evidence associated with each of the
above listed seven patient-important primary and sec-
ondary outcomes [63]. ‘Summary of findings’ tables will
be constructed using GRADEpro software (https://gra-
depro.org/). The GRADE approach appraises the quality
of a body of evidence in order to assess the certainty in
the effect estimates. The quality measures of a body of
evidence considers within-study risk of bias, inconsist-
ency of the results, indirectness of evidence, imprecision,
and reporting bias [63]. We will conduct a subgroup
analysis comparing pooled effect estimates between trials
at low (or if no, at relative lower) risk of bias to trials at
high risk of bias [96]. If no difference is detected, the
summery of findings tables will be based on the overall
analysis [66–70, 97, 98].
Discussion
This systematic review will aim at synthesising the evi-
dence on the effects of prothrombin complex concen-
trate in the treatment of critically bleeding patients
treated with oral anticoagulants. Intracranial bleeding is
in general believed to be one of the most feared compli-
cations of treatment with anticoagulation agents. It is
also the aim of this review to assess the evidence regard-
ing the treatment effect of prothrombin complex con-
centrate in patients with intracranial bleeding.
This protocol has a number of strengths. The predefined
methodology is based on the Cochrane Handbook for
Systematic Reviews of Interventions [64], the eight-step
assessment suggested by Jakobsen and colleagues [75],
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trial sequential analysis [81, 82, 85], and GRADE assess-
ment [99]. Hence, this protocol takes into account both
risks of systematic errors and risk of random errors as well
as the quality of the evidence.
Our protocol also has a number of limitations. We
plan to include trials randomising different patient pop-
ulations, and it must consequently be expected that we
will include patients with different sources of bleeding
as well as patients with different severity of bleeding
[100].These factors may introduce heterogeneity, which
will be sought investigated in subgroup analysis of the
different patient populations. Another limitation is the
expected use of different ways to adjudicate the same
outcome measurements between trials (e.g. different
scales to assess functional outcome) along with an ex-
pected variability in follow-up time. As we only include
randomised trials, rare or late important safety events
might be underreported [101, 102]. A final limitation is
that we were aware of both previous reviews and also
previous trials assessing the effects of prothrombin com-
plex concentrate, which might result in data-driven
methodology.
A Cochrane review [61] has assessed the evidence of the
effects of prothrombin complex concentrate in patients
treated with vitamin K antagonists. However, since the
publication of this review, new randomised clinical trials
have been conducted evaluating prothrombin complex
concentrate to reverse vitamin K antagonist treatment, es-
pecially in patients with intracranial haemorrhage. In
addition, non-vitamin K antagonist oral anticoagulants
have become increasingly popular [5].
It is our intension in the planned systematic review to
include and evaluate all randomised clinical trials con-
ducted evaluating prothrombin complex concentrate in
critically bleeding patients. We hope that this review will
be able to guide best practice, when treating this patient
group or planning future clinical research for this pa-
tient group.
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